The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Expires: July 31, 2015
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Century Therapeutics, Inc. Common Stock 15673T100 27,495,406 12,166,109 SH OTR 0 12,166,109 0
Contineum Therapeutics, Inc. Common Stock 21217B100 7,086,722 542,628 SH OTR 0 542,628 0
CRISPR Therapeutics AG Common Shares H17182108 7,079,891 148,831 SH OTR 0 148,831 0
Jade Biosciences, Inc. Common Stock 008064206 21,437,771 1,525,820 SH OTR 0 1,525,820 0
Lenz Therapeutics, Inc. Common Stock 52635N103 24,310,525 2,656,888 SH OTR 0 2,656,888 0
Monte Rosa Therapeutics, Inc. Common Stock 61225M102 52,323,831 3,180,780 SH OTR 0 3,180,780 0
Skye Bioscience, Inc. Common Stock 83086J200 1,233,935 2,007,704 SH OTR 0 2,007,704 0
Tempest Therapeutics, Inc. Common Stock 87978U108 442,426 269,772 SH OTR 0 269,772 0